470 filings
Page 2 of 24
4
853v6p fjk3
26 Mar 24
Crinetics Pharmaceuticals / Jeff E. Knight ownership change
4:30pm
4
887jbu3ql06704uj
22 Mar 24
Crinetics Pharmaceuticals / Dana Pizzuti ownership change
4:52pm
4
5vsicjv771kscxvch
22 Mar 24
Crinetics Pharmaceuticals / Matthew K Fust ownership change
4:31pm
144
y2ivij4qtjwrql29cq
22 Mar 24
Notice of proposed sale of securities
2:34pm
144
femey
21 Mar 24
Notice of proposed sale of securities
5:20pm
4
ynieck1
20 Mar 24
Crinetics Pharmaceuticals / Dana Pizzuti ownership change
6:36pm
4
u7r6dhu86p82n7q8auw
20 Mar 24
Crinetics Pharmaceuticals / Jeff E. Knight ownership change
6:35pm
4
c1fm1em maq
20 Mar 24
Crinetics Pharmaceuticals / James Hassard ownership change
6:34pm
4
f3yml p1ptm1ojpqj5
20 Mar 24
Crinetics Pharmaceuticals / Stephen F. Betz ownership change
6:33pm
4
py2 mfeles
20 Mar 24
Crinetics Pharmaceuticals / Marc Wilson ownership change
6:32pm
4
tgzo nwieurm1larb
20 Mar 24
Crinetics Pharmaceuticals / Richard Scott Struthers ownership change
6:31pm
144
vl8ml7ntyk
20 Mar 24
Notice of proposed sale of securities
5:37pm
144
vl2rj4dosx
20 Mar 24
Notice of proposed sale of securities
4:40pm
144
7yw6sfddus06j5ylaav
19 Mar 24
Notice of proposed sale of securities
4:22pm
S-3ASR
1u8uk6
19 Mar 24
Automatic shelf registration
4:05pm
8-K
ilha68i
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
8-K
uhoxvz
12 Mar 24
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
4:25pm
D
wics2a54m4ou9o
11 Mar 24
$350.00 mm in equity, sold $350.00 mm, 36 investors
4:15pm
SC 13G
ct76 7ueovoy
11 Mar 24
Crinetics Pharmaceuticals / EcoR1 Capital ownership change
3:34pm
4
zycd 4qv9jngikd77b0
6 Mar 24
Crinetics Pharmaceuticals / James Hassard ownership change
8:18pm